Compare ROCK & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROCK | ABCL |
|---|---|---|
| Founded | 1972 | 2012 |
| Country | United States | Canada |
| Employees | 2221 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 1996 | 2020 |
| Metric | ROCK | ABCL |
|---|---|---|
| Price | $37.45 | $5.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.40 |
| AVG Volume (30 Days) | 326.8K | ★ 8.5M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,135,501,000.00 | $75,128,000.00 |
| Revenue This Year | $41.26 | N/A |
| Revenue Next Year | $20.14 | $21.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $33.56 | $1.98 |
| 52 Week High | $75.08 | $6.52 |
| Indicator | ROCK | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 50.92 | 63.20 |
| Support Level | $37.77 | $3.45 |
| Resistance Level | $40.84 | $5.63 |
| Average True Range (ATR) | 1.73 | 0.41 |
| MACD | 0.16 | 0.04 |
| Stochastic Oscillator | 62.64 | 74.56 |
Gibraltar Industries Inc manufactures and provides products and services for the Renewable energy, Residential, Agtech, and Infrastructure markets. The Renewable Segment is engaged in designing, engineering, manufacturing, and installing solar racking and electrical balance systems. Agtech Segment provides growing and processing solutions including the designing, engineering, manufacturing, full-scope construction, maintenance, and support of greenhouses and indoor growing operations, and botanical extraction systems. It derives key revenue from the Residential segment which offers roof and foundation ventilation products, single point and centralized mail systems electronic package solutions, and Retractable awnings and gutter guards, among other products.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.